Amgen announces romosozumab Phase 2 trial outcomes in postmenopausal females with low BMD Amgen and UCB today announced results from a Phase 2 trial evaluating romosozumab in postmenopausal females with low bone mineral density . Released in the New England Journal of Medication , the trial demonstrated that, weighed against placebo, romosozumab treatment for 12 a few months elevated BMD at the lumbar spine significantly, total hip and femoral throat. Significant boosts were also observed in the first BMD assessment at 90 days.D., director of the Oregon Osteoporosis Center and lead study investigator. ‘Additionally, romosozumab treatment resulted in greater raises in bone mineral density than those noticed with both placebo and the active comparators.Nevertheless, rural cancer sufferers were 66 % much more likely to retire early as a result of their analysis than their urban counterparts. This disparity is certainly ascribed to the actual fact that rural populations tend to engage in more physically demanding jobs, for instance in construction, agriculture, mining and forestry, which they are unable to pursue after their cancer treatment. Another finding is normally that malignancy survivors in rural areas had been 33 % less inclined to continue paid disability while receiving cancer tumor treatment than their urban counterparts of comparable age, cancer and education stage.